
Essential Certificate of Origin Checks Most Buyers Miss
A certificate of origin states where the drums were made — and nothing else. Which version your shipment needs, and the checks that keep it from stalling at customs.
Table of Contents
In the pharmaceutical industry, many quality issues do not originate at the API (Active Pharmaceutical Ingredient) stage, but rather at the earlier, often overlooked stage of Pharmaceutical Intermediates.
My particular focus on “impurity control” stems not from its fancy terminology, but from decades of production experience revealing that 80% of factors affecting final API quality can be prevented at the intermediate stage.
This article is grounded in practical experience, eschewing abstract theory to share key insights distilled from real-world manufacturing. We’ll discuss pitfalls encountered in impurity control, patterns observed, and actionable solutions.
If API quality is likened to a building’s stability, then pharmaceutical intermediates form its foundation.
Many companies focus quality control at the API end, but our long-term project experience reveals:
In other words, leading API manufacturers prioritize quality control starting from intermediates.
Based on observations across diverse projects, intermediate impurities stem from four primary categories:
① Raw Material Impurities: Raw material quality determines the initial impurity baseline
Example: Aromatic amine raw materials often contain low-level byproducts. Without prior assessment, subsequent condensation and addition reactions amplify these impurities.
② Reaction byproducts: Influenced by temperature/ratio/pH
Our most typical example:
In a hydrogenation process, merely adjusting the heating rate by 2–3°C resulted in a 20% difference in byproduct ratio.
Such impurities are often difficult to predict through testing alone and require practical batch experience.
③ Residual solvents and catalysts: Easily overlooked issues
Many testing methods focus more on structure-related impurities, while residual solvents (e.g., DMF) and catalysts (Pt/C, Pd/C) are more likely to be neglected.
Yet these are often the points of greatest concern to customers.
④ Human and Process Environmental Factors
Includes:
These issues lie beyond SOPs (Standard Operating Procedures) and cannot be resolved solely through documentation; they require iterative experience.
These methods have been repeatedly validated across dozens of intermediate projects and are shared for reference.
① Establish an “Impurity Baseline”
Many companies rush to optimize processes from the outset, but we recommend first answering this question:
“What impurities consistently appear under the most basic process conditions? Where do they originate?”
The value of an impurity baseline lies in:
② Employ Cross-Verification with Multiple Detection Methods, Not Just HPLC
HPLC provides only one-dimensional impurity information. In actual projects, we utilize:
Especially LC–MS, which enables earlier impurity structural identification and facilitates root cause analysis.
③ Subject PV batches to “extreme condition challenges”
During PV (Process Validation), we deliberately subject batches to extreme conditions, such as:
The rationale is straightforward:
Real production never occurs under “perfect conditions.” Clients will ask: “Can your impurity control remain stable under extreme conditions?”
④ Keep IPCs minimal but precise
We often see companies adding excessive IPC metrics to appear “stricter,” which actually creates operational chaos.
Our experience-based principles:
✔ Keep IPCs lean and focused (2–3 is sufficient)
✔ Each IPC must significantly influence impurity trends
✔ Test only critical points—not “all parameters”
Example: For condensation reactions, prioritize:
This approach enhances control effectiveness and consistency.
⑤ Establish a “Batch-to-Batch Impurity Tracking Model”
We create trend charts for critical impurity data across each batch, focusing on three points:
This allows us to predict potential quality risks 1–2 months in advance.
To enhance practicality, here’s an evaluation method we often share with clients:
When assessing an intermediate supplier, these questions are critical:
If the supplier cannot answer these questions, their impurity control capabilities are likely limited.
Impurity control for pharmaceutical intermediates cannot be resolved with a simple statement like “We strictly adhere to GMP.”
It requires:
More importantly, it must rely on real-world experience.
We hope this article provides you with a deeper, practical understanding of “impurity control in pharmaceutical intermediates.” If you encounter difficulties with impurities in a specific intermediate, we can also assist in analyzing the process mechanisms.
For technical exchanges and sample services, please contact Tianming Pharmaceutical Group’s online representatives:
Email: sunqian0123@gmail.com/WhatsApp: +8617663713557

A certificate of origin states where the drums were made — and nothing else. Which version your shipment needs, and the checks that keep it from stalling at customs.

A certificate of analysis shows numbers; a certificate of conformity shows confidence. Which one your shipment actually needs depends on the decision someone downstream is going to make with it.

Batch and lot can point at the same drums and still disagree on paper. Seven places where the two identifiers split, and the one line worth writing down before the truck leaves.
Tianming Pharmaceutical is a manufacturer of high-quality pharmaceutical intermediates and fine chemicals for research, development and industrial synthesis. We support global B2B partners with process development, custom synthesis and reliable supply, backed by consistent quality documentation.
Products are supplied as pharmaceutical intermediates for research and industrial use only. They are not for human or veterinary use and are not intended for the manufacture of finished pharmaceutical products without independent regulatory authorization.